Orion Oyj

Board/Management Information • Oct 28, 2019

Disclosure 375978

Orion - Other information disclosed according to the rules of the Exchange

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE 28 OCTOBER 2019 at 19.30 EET

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

• Annika Ekman
• Erkki Etola
• Petteri Karttunen
• Matti Kavetvuo
• Timo Maasilta
• Heikki Westerlund
• Jukka Ylppö

Heikki Westerlund was elected Chairman of the Committee.

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website.

Orion Corporation

Timo Lappalainen President and CEO		Olli Huotari SVP, Corporate Functions

Contact person:

Timo Lappalainen, President and CEO

tel. +358 10 426 3692

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.